Q3 FY2026
Filed Nov 10, 2026Atara reports Q3 2026 commercialization revenue of $1.2 million, down from $3.5 million, as operating costs fall; cash of $9.9 million funds operations into mid-2027
Quarterly revenue fell year over year to $1.2 million from $3.5 million, and the company attributes the decline to a one-time prior-year sale of clinical inventory. Costs and the net loss narrowed sharply, and the nine-month cost reduction is stated as approximately 83%. Cash, cash equivalents and short-term investments of $9.9 million, a stockholders' deficit of $(37,902) thousand, and a going concern risk factor leave the company dependent on the tab-cel approval outcome, which rests with Pierre Fabre Pharmaceuticals.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Commercialization revenue (total revenues), three months ended Sept 30, 2026GAAP | $1.22M | – | decreased by $2.3 million |
| Cost of commercialization revenue, three months ended Sept 30, 2026GAAP | $265K | – | – |
| Research and development expenses, three months ended Sept 30, 2026GAAP | $1.10M | – | – |
| General and administrative expenses, three months ended Sept 30, 2026GAAP | $2.83M | – | – |
| Total costs and operating expenses, three months ended Sept 30, 2026GAAP | $4.19M | – | – |
| Income (loss) from operations, three months ended Sept 30, 2026GAAP | −$2.97M | – | – |
| Interest income, three months ended Sept 30, 2026GAAP | $68K | – | – |
| Interest income (expense) on sale of future revenues, three months ended Sept 30, 2026GAAP | $682K | – | – |
| Total other income (expense), net, three months ended Sept 30, 2026GAAP | $741K | – | – |
| Income (loss) before income taxes, three months ended Sept 30, 2026GAAP | −$2.23M | – | – |
| Net income (loss), three months ended Sept 30, 2026GAAP | −$2.23M | – | – |
| Basic and diluted (loss) earnings per common share, three months ended Sept 30, 2026GAAP | $(0.15) | – | – |
| Net loss (text), three months ended Sept 30, 2026GAAP | $2.2M | – | – |
| Net cash used in operating activities, three months ended Sept 30, 2026other | $900K | – | – |
| Non-cash stock-based compensation, depreciation and amortization included in costs and operating expenses, three months ended Sept 30, 2026other | $500K | – | – |
| Non-cash stock-based compensation included in research and development expenses, three months ended Sept 30, 2026other | $100K | – | – |
| Non-cash stock-based compensation included in general and administrative expenses, three months ended Sept 30, 2026other | $400K | – | – |
| Commercialization revenue (total revenues), nine months ended Sept 30, 2026GAAP | $2.37M | – | – |
| Cost of commercialization revenue, nine months ended Sept 30, 2026GAAP | $580K | – | – |
| Research and development expenses, nine months ended Sept 30, 2026GAAP | $2.61M | – | – |
| General and administrative expenses, nine months ended Sept 30, 2026GAAP | $10.24M | – | – |
| Total costs and operating expenses, nine months ended Sept 30, 2026GAAP | $13.43M | – | – |
| Income (loss) from operations, nine months ended Sept 30, 2026GAAP | −$11.06M | – | – |
| Interest income, nine months ended Sept 30, 2026GAAP | $199K | – | – |
| Interest income (expense) on sale of future revenues, nine months ended Sept 30, 2026GAAP | −$333K | – | – |
| Total other income (expense), net, nine months ended Sept 30, 2026GAAP | −$148K | – | – |
| Income (loss) before income taxes, nine months ended Sept 30, 2026GAAP | −$11.21M | – | – |
| Net income (loss), nine months ended Sept 30, 2026GAAP | −$11.21M | – | – |
| Basic (loss) earnings per common share, nine months ended Sept 30, 2026GAAP | $(0.76) | – | – |
| Diluted (loss) earnings per common share, nine months ended Sept 30, 2026GAAP | $(0.76) | – | – |
| Nine-month reduction in costs and operating expenses (as stated in headline)other | approximately 83% | – | – |
| Cash, cash equivalents and short-term investments as of Sept 30, 2026other | $9.9M | – | – |
| Total assets as of Sept 30, 2026GAAP | $18.61M | – | – |
| Total liabilities as of Sept 30, 2026GAAP | $56.51M | – | – |
| Total stockholders' equity (deficit) as of Sept 30, 2026GAAP | −$37.90M | – | – |
2026 (qualitative outlook) outlook
- NoteOperating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026.
- NoteCash, cash equivalents and short-term investments as of Sept 30, 2026, combined with operating efficiencies achieved in 2025 and the first half of 2026, are expected to be sufficient to fund planned operations into mid-2027.
- NoteFDA Class 2 Resubmission PDUFA target action date for tabelecleucel is March 31, 2027. If approved, Atara would be eligible to receive a $31 million milestone payment from Pierre Fabre Laboratories.
Capital returns
- No share repurchases or dividends are reported in the filing.
What drove it
- Company explanation: total revenues decreased by $2.3 million year-over-year, primarily due to the one-time sale of clinical inventory in the prior year.
- Company explanation: operating expenses are expected to decline significantly year-over-year, reflecting the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026.
- Company statement: the resubmission of the tab-cel BLA, with a Class 2 Resubmission PDUFA target action date of March 31, 2027, is described as an important milestone this quarter.
- The filing states that Atara would be eligible for a $31 million milestone payment from Pierre Fabre Laboratories if tabelecleucel is approved, plus double-digit tiered royalties on net sales and commercial milestones.
Concerns
- Commercialization revenue fell from $3,453 thousand to $1,224 thousand in the quarter, and from $119,177 thousand to $2,370 thousand in the nine months. The filing ties the quarterly decline to the prior-year clinical inventory sale.
- Cash, cash equivalents and short-term investments of $9.9 million were unchanged from June 30, 2026, and the company guides to funding operations into mid-2027.
- Total liabilities of $56,509 thousand exceed total assets of $18,607 thousand, giving a stockholders' deficit of $(37,902) thousand as of Sept 30, 2026.
- The forward-looking statements list the ability to continue as a going concern among the risks.
- The filing states that PFP, not Atara, holds the tab-cel BLA and controls its content and strategy, and that Atara's ability to influence the review process is limited.
- Interest income (expense) on sale of future revenues was $682 thousand in Q3 2026 against $(906) thousand in Q3 2025. The filing does not explain the change.
What to watch
- FDA review of the resubmitted tab-cel BLA, with the PDUFA target action date of March 31, 2027.
- Receipt of the $31 million milestone payment from Pierre Fabre Laboratories if tabelecleucel is approved.
- Whether operating expenses continue to decline significantly year-over-year as guided.
- Cash runway into mid-2027 and any access to additional capital, which the filing identifies as a risk factor.
- Revenue trajectory after the prior-year inventory sale, given that Q3 2026 revenue was $1,224 thousand.
Balance sheet and cash flow
- Cash and cash equivalents of $4,055 thousand and short-term investments of $5,862 thousand as of Sept 30, 2026, versus cash and cash equivalents of $8,482 thousand and no short-term investments as of December 31, 2025.
- Accounts receivable $691 thousand as of Sept 30, 2026 versus $1,253 thousand as of December 31, 2025.
- Total current liabilities $6,568 thousand as of Sept 30, 2026 versus $14,922 thousand as of December 31, 2025.
- Liability related to the sale of future revenues: current portion $1,105 thousand and long-term $39,560 thousand as of Sept 30, 2026, versus $9,750 thousand and $32,673 thousand as of December 31, 2025.
- Accumulated deficit $(2,033,073) thousand as of Sept 30, 2026 versus $(2,021,865) thousand as of December 31, 2025.
- Shares issued and outstanding 10,188 thousand as of Sept 30, 2026 versus 7,324 thousand as of December 31, 2025.
- Net cash used in operating activities was $0.9 million for Q3 2026, compared with $9.8 million in Q3 2025. The filing does not print a nine-month operating cash flow figure.
Analysis
Atara reported third-quarter 2026 commercialization revenue of $1,224 thousand, against $3,453 thousand in the third quarter of 2025. The company attributes the $2.3 million year-over-year decrease primarily to a one-time sale of clinical inventory in the prior-year quarter. Nine-month revenue was $2,370 thousand, against $119,177 thousand a year earlier, a comparison the filing does not explain beyond the figures themselves. The filing gives no product-level or geographic revenue breakdown, so the revenue read rests on the consolidated line.
Cost reduction is the most visible change. Third-quarter total costs and operating expenses were $4,194 thousand, against $7,027 thousand, with research and development at $1,099 thousand (against $2,925 thousand) and general and administrative at $2,830 thousand (against $3,987 thousand). For the nine months, total costs and operating expenses were $13,429 thousand, against $80,752 thousand, and the headline states a nine-month reduction of approximately 83%. The company links the lower expense base to the full-year benefit of cost-reduction initiatives implemented in 2025 and the first half of 2026. Loss from operations narrowed to $(2,970) thousand from $(3,574) thousand, and the net loss to $(2,229) thousand from $(4,303) thousand, or $(0.15) per share against $(0.32). Operating cash use was $0.9 million against $9.8 million.
The balance sheet is the main constraint. Cash, cash equivalents and short-term investments were $9.9 million at September 30, 2026, the same figure as at June 30, 2026. Total assets were $18,607 thousand and total liabilities were $56,509 thousand, leaving a stockholders' deficit of $(37,902) thousand. The liability related to the sale of future revenues stood at $1,105 thousand current and $39,560 thousand long-term. The company states that its existing cash and the efficiencies achieved will fund planned operations into mid-2027. The forward-looking statements also list the ability to continue as a going concern among the risks.
The filing has no numeric 2026 guidance. Its outlook is qualitative: operating expenses are expected to decline significantly year-over-year, and cash is expected to last into mid-2027. The key value event is the tabelecleucel BLA resubmission, which carries a PDUFA target action date of March 31, 2027, and a $31 million milestone payment from Pierre Fabre Laboratories on approval. The filing states that PFP, not Atara, holds the BLA and controls its strategy, and that Atara's influence over the review is limited. Interest income (expense) on the sale of future revenues swung to $682 thousand from $(906) thousand; the filing does not explain that line.
Management, verbatim
The resubmission of the tab-cel BLA was an important milestone this quarter, and we remain focused on supporting Pierre Fabre Pharmaceuticals (PFP) toward a successful outcome,
Cokey Nguyen, President and Chief Executive Officer, Atara Biotherapeutics
We continue to believe in tab-cel’s significant commercial potential in the U.S.
Cokey Nguyen, President and Chief Executive Officer, Atara Biotherapeutics
In parallel, we are taking steps to control expenses with the goal of protecting and maximizing shareholder value while enhancing our strategic flexibility.
Cokey Nguyen, President and Chief Executive Officer, Atara Biotherapeutics
Not in the filing
stated, not guessed- No prior outlook was provided, so vs_prior_guidance is empty.
- The filing gives no numeric 2026 guidance for revenue, gross margin, operating expenses or tax rate.
- Prior-year and prior-quarter comparisons are not printed for the cost, expense, loss from operations, other income and per-share lines, so those fields are null.
- Year-over-year change percentages are not printed for any line item other than the revenue decrease stated in dollars.
- The filing does not state the basis (GAAP or otherwise) of the financial statement lines or the cash-flow figures; those are marked as printed without a labelled basis.
- No nine-month operating cash flow or nine-month cash flow statement is printed.
- No segment or product-level revenue breakdown is provided.
- Income tax provision for Q3 2026 is printed as a dash, and the nine-month provision of $1 thousand (2026) and $31 thousand (2025) is not shown as a separate key metric.
- Dollar comparisons for Dec 31, 2025 balance sheet items are not prior-year figures and are kept in balance_sheet_cash_flow only.
- The filing does not state why interest income (expense) on the sale of future revenues changed from $(906) thousand to $682 thousand in the quarter.
- No share repurchases or dividends are reported.
- No share price reaction or analyst consensus is included in the filing.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.